RESEARCHER PROFILE
Gül Başaran
G
Acıbadem University
Gül Başaran works in Breast Cancer Treatment Studies, Breast Lesions and Carcinomas, HER2/EGFR in Cancer Research, Gastric Cancer Management and Outcomes, Advanced Breast Cancer Therapies. Recorded institutional associations include Acıbadem University.
175Publications
2,125Citations
19H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · 585 citationsEvaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
2008 · 348 citationsTaxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer
2008 · 216 citationsHPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples.
2006 · 97 citationsFinal Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
2024 · 91 citationsThe association between individual attachment patterns, the perceived social support, and the psychological well‐being of Turkish informal caregivers
2009 · 68 citationsProlonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer
2009 · 49 citationsOngoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
2017 · 48 citationsAnti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial
2007 · 47 citationsReview of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials
2015 · 45 citationsVascular Endothelial Growth Factor, Hypoxia-Inducible Factor 1 Alpha and CD34 Expressions in Early-Stage Gastric Tumors: Relationship with Pathological Factors and Prognostic Impact on Survival
2007 · 40 citationsA European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
2015 · 36 citationsDe-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer
2025 · 30 citationsWeight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey
2010 · 29 citationsEpithelioid hemangioendothelioma with multiple organ involvement
2007 · 28 citationsDatopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
2026 · 26 citationsTreatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
2023 · 24 citationsClinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?
2010 · 21 citationsImpact of body mass index on cancer development.
2008 · 12 citationsPertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes
2018 · 12 citationsTurkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak
2020 · 12 citationsCombined analysis of the MF18‐02/MF18‐03 NEOSENTITURK studies: ypN‐positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided
2024 · 12 citationsSerum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer
2012 · 11 citationsA case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion.
2009 · 10 citationsClinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience
2014 · 10 citations
